This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ProMIS Neurosciences Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for ProMIS Neurosciences.

Wichtige Informationen

9.3%

Wachstumsrate der Gewinne

13.3%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	39.0%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	17 Jul 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We're A Little Worried About ProMIS Neurosciences' (TSE:PMN) Cash Burn Rate

Oct 11

Despite Lacking Profits ProMIS Neurosciences (TSE:PMN) Seems To Be On Top Of Its Debt

Jun 23

Is ProMIS Neurosciences (TSE:PMN) A Risky Investment?

Mar 07

Is ProMIS Neurosciences (TSE:PMN) A Risky Investment?

Nov 19

Gewinn- und Umsatzwachstumsprognosen

TSX:PMN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	N/A	-18	N/A	N/A	1
12/31/2024	N/A	-14	N/A	N/A	1
12/31/2023	N/A	-17	N/A	N/A	1
3/31/2023	N/A	-21	-16	-16	N/A
12/31/2022	N/A	-18	-17	-17	N/A
9/30/2022	0	-12	-16	-16	N/A
6/30/2022	0	-8	-15	-15	N/A
3/31/2022	N/A	-6	-12	-12	N/A
12/31/2021	N/A	-10	-9	-9	N/A
9/30/2021	N/A	-8	-6	-6	N/A
6/30/2021	N/A	-8	-4	-4	N/A
3/31/2021	0	-9	-3	-3	N/A
12/31/2020	0	-4	-4	-3	N/A
9/30/2020	0	-5	-4	-4	N/A
6/30/2020	0	-5	-4	-4	N/A
3/31/2020	0	-5	-4	-4	N/A
12/31/2019	0	-6	-5	-5	N/A
9/30/2019	0	-7	-6	-6	N/A
6/30/2019	0	-8	-7	-7	N/A
3/31/2019	0	-8	-7	-7	N/A
12/31/2018	0	-7	-6	-6	N/A
9/30/2018	0	-6	-6	-6	N/A
6/30/2018	0	-5	-5	-5	N/A
3/31/2018	0	-5	-5	-5	N/A
12/31/2017	0	-5	-5	-5	N/A
9/30/2017	0	-5	-4	-4	N/A
6/30/2017	0	-4	-3	-3	N/A
3/31/2017	0	-3	-3	-3	N/A
12/31/2016	0	-3	N/A	-2	N/A
9/30/2016	0	-2	N/A	-2	N/A
6/30/2016	0	-2	N/A	-2	N/A
3/31/2016	0	-2	N/A	-2	N/A
12/31/2015	0	-2	N/A	-1	N/A
9/30/2015	0	-1	N/A	-1	N/A
6/30/2015	0	-2	N/A	-1	N/A
3/31/2015	0	-2	N/A	-1	N/A
12/31/2014	0	-2	N/A	-2	N/A
9/30/2014	0	-3	N/A	-2	N/A
6/30/2014	0	-2	N/A	-2	N/A
3/31/2014	0	-2	N/A	-2	N/A
12/31/2013	0	-2	N/A	-1	N/A
9/30/2013	0	-2	N/A	-1	N/A
6/30/2013	0	-2	N/A	-2	N/A
3/31/2013	0	-2	N/A	-2	N/A
12/31/2012	0	-2	N/A	-2	N/A
9/30/2012	0	-3	N/A	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: PMN is forecast to remain unprofitable over the next 3 years.

Ertrag vs. Markt: PMN is forecast to remain unprofitable over the next 3 years.

Hohe Wachstumserträge: PMN is forecast to remain unprofitable over the next 3 years.

Einnahmen vs. Markt: Insufficient data to determine if PMN's revenue is forecast to grow faster than the Canadian market.

Hohe Wachstumseinnahmen: PMN is forecast to have no revenue next year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if PMN's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

ProMIS Neurosciences Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

No longer forecast to breakeven

Recent updates

ProMIS Neurosciences to Delist from TSX

ProMIS Neurosciences Inc. Announces FDA Clearance of Investigational New Drug Application for PMN310 in Alzheimer’s Disease

No longer forecast to breakeven

ProMIS Neurosciences, Inc. announced that it has received $7.472277 million in funding from Kraft Group LLC and other investors

We're A Little Worried About ProMIS Neurosciences' (TSE:PMN) Cash Burn Rate

ProMIS Neurosciences Appoints Gail M. Farfel as Chief Executive Officer

ProMIS Neurosciences, Inc. to Present At 2022 Alzheimer's Association International Conference

ProMIS Neurosciences Common Shares Deleted from Other OTC

Chairman & CEO recently bought CA$64k worth of stock

Despite Lacking Profits ProMIS Neurosciences (TSE:PMN) Seems To Be On Top Of Its Debt

ProMIS Neurosciences, Inc. Appoints Larry Altstiel as Chief Medical Officer

Full year 2021 earnings: EPS misses analyst expectations

Is ProMIS Neurosciences (TSE:PMN) A Risky Investment?

ProMIS Neurosciences, Inc. Announces Pmn310 Antibody Demonstrates Significant Cognitive Benefit in A Mouse Model of Alzheimer’s Disease

ProMIS Neurosciences, Inc. Announces Board Appointments

ProMIS Neurosciences Appoints Cheryl Wellington to its Scientific Advisory Board

ProMIS Neurosciences, Inc. Initiates Program to Develop Monoclonal Antibodies to Treat Schizophrenia and Other Chronic Mental Illnesses

Is ProMIS Neurosciences (TSE:PMN) A Risky Investment?

ProMIS Neurosciences, Inc. has completed a Composite Units Offering in the amount of $17.5 million.

ProMIS Neurosciences, Inc. Initiates Commercialization of Covid-19 Serology Assay

ProMIS Neurosciences Re-Initiates Path to IND for PMM310 with Producer Cell Line Development

Full year 2020 earnings released: CA$0.02 loss per share (vs CA$0.028 loss in FY 2019)

ProMIS Neurosciences, Inc. announced that it has received CAD 8.75 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences, Inc. Announces Perspectives on Recent Progress in the Alzheimer's Field

Earnings miss expectations

ProMIS Neurosciences Adds Dr. David Wishart to Its Scientific Advisory Board

ProMIS Neurosciences, Inc. Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference

ProMIS Neurosciences, Inc. Announces Resignation of Anthony Giovinazzo from the Board of Directors

ProMIS Neurosciences, Inc. to Develop Multivalent Vaccine for Alzheimer’s Disease

Earnings released

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken